Pfizer's Thelin Withdrawn Due to Fatalities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pfizer's Thelin Withdrawn Due to Fatalities

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin (sitaxentan) from the worldwide market and discontinued all ongoing trials. The drug had been approved in the European Union (EU) , Canada, and Australia for the treatment of pulmonary arterial hypertension (PAH).

The withdrawal was based on a review of emerging safety information from clinical trials and post-marketing reports. Thelin belongs to class of drugs of which liver toxicity is a known complication. As such, the treatment has been contra-indicated in patients with mild to severe hepatic impairment and elevated aminotransferases prior to initiation of treatment. In a press statement, however, Pfizer said, “Given the availability of alternate treatments, Pfizer has concluded that the overall benefit of Thelin no longer outweighs the risk in the general population of PAH patients.”

The company has recommended that no new patients be prescribed Thelin and that current patients be transitioned to alternate therapies as soon as safely possible. In a statement, EMA also added that patients currently taking Thelin are advised not to stop the treatment and to consult their physician to review their treatment at their next scheduled appointment.

Pfizer acquired Thelin after buying Encysive Pharmaceuticals (Houston, TX) in 2008. The treatment was authorized for use in the EU in 2006. On the other side of the Atlantic, however, the US Food and Drug Administration refused to approve the drug on three different occasions because of safety concerns. Pfizer had been trying to alleviate these with new clinical studies, which have now been discontinued. 


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here